Target intelligence / Profile preview

T cell receptor alpha joining 49 (TRAJ49)

Target
TRAJ49
Molecular classification
Receptor component, T cell receptor joining gene, Immune receptor gene segment
01

Overview

TRAJ49 (T cell receptor alpha joining 49) is a gene segment in the human T cell receptor alpha (TRA) locus, coding for one of the joining (J) regions used in the recombination process during T cell receptor (TCR) alpha chain assembly. The TCR complex is critical for immune recognition of peptide antigens presented by MHC molecules on antigen-presenting cells. TRAJ49 does not encode a standalone protein but instead, contributes one of the potential J segments that can be chosen when TCR alpha chain genes rearrange in developing T cells, generating the diverse antigen specificity required for immune defense[1][3][7]. TRAJ49 is not a drug target on its own but is important for normal T cell function and immune diversity. Variation in the usage of such J segments can be assessed in studies of TCR repertoire but is not directly targeted therapeutically or used as a biomarker[1][7]. Note: TRAJ49, as per nomenclature and genomic databases, is a joining gene segment (not a full protein) within the T cell receptor alpha locus, fundamental for TCR diversity but not a direct therapeutic target or biomarker[1][7].

Other names
TRAJ49T-cell receptor alpha joining 49
02

Mechanism of action

Not applicable (TRAJ49 is a gene segment and not a distinct druggable protein)

03

Biological functions

Antigen recognition (as part of the T cell receptor complex)Immune response (via T cell receptor assembly and specificity)
04

Disease associations

Other (dysregulation of T cell receptor genes may broadly affect immune function and potentially immune-related diseases, but TRAJ49 itself is not directly implicated in specific diseases)
05

Safety considerations

None specific to TRAJ49 (no known direct safety concerns)
06

Interacting drugs

None (no direct drugs interact with TRAJ49; drugs targeting the T cell receptor complex or T cells affect the receptor holistically)
07

Biomarkers

None specific (not individually used as a biomarker; TCR repertoire analyses may include TRAJ49 usage pattern)

Beyond the preview

Go deeper on T cell receptor alpha joining 49 (TRAJ49).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 49 (TRAJ49).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call